
X
Sarepta goes up, PTC goes down – DMD research sways the market
https://pharmaphorum.com/news/dmd-therapy-research-sways-market/
Project will initially focus on DMD but could benefit other rare diseases
FDA staff not persuaded by patchy clinical trial evidence for Translarna.
PTC says it will make changes to the price after abandoned launch last month.
US biotech seeks conditional approval for eteplirsen in EU.